公开(公告)号：US20170016903A1

公开(公告)日：2017-01-19

申请号：US15121783

申请日：2015-03-02

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Ashley E. ROSS ,  Edward M. SCHAEFFER ,  Luigi MARCHIONNI

IPC: G01N33/574

CPC classification number: G01N33/57434 ,  G01N2800/50 ,  G01N2800/52 ,  G01N2800/56 ,  G01N2800/60

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides compositions and methods for identification of individuals having clinically significant cancer. In one embodiment, a method for treating a subject having prostate cancer comprises the steps of (a) obtaining a biological sample from the subject; (b) performing an assay on the sample obtained from the subject to measure the levels of one or more protein biomarkers listed in Table 1; (c) comparing the measured levels of one or more protein biomarkers to one or more reference controls to identify the subject as having high grade prostate cancer, low grade prostate cancer or no prostate cancer; and (d) treating the subject with one or more treatment modalities appropriate for a subject having high grade prostate cancer or low grade prostate cancer.

Abstract translation: 本发明涉及癌症领域。 更具体地，本发明提供用于鉴定具有临床重要性癌症的个体的组合物和方法。 在一个实施方案中，用于治疗患有前列腺癌的受试者的方法包括以下步骤：（a）从受试者获得生物样品; （b）对从受试者获得的样品进行测定以测量表1中列出的一种或多种蛋白质生物标志物的水平; （c）将一种或多种蛋白质生物标志物的测量水平与一种或多种参考对照进行比较，以将受试者鉴定为具有高等级前列腺癌，低级前列腺癌或无前列腺癌; 和（d）用适合于具有高等级前列腺癌或低等级前列腺癌的受试者的一种或多种治疗方式治疗受试者。

公开(公告)号：US20160130662A1

公开(公告)日：2016-05-12

申请号：US14899352

申请日：2014-06-17

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Paula J. HURLEY ,  Edward M. SCHAEFFER

IPC: C12Q1/68

CPC classification number: C12Q1/6886 ,  C12Q2600/118 ,  C12Q2600/156

Abstract: The present invention relates to the field of cancer. More specifically, the present invention provides methods and compositions useful for assessing prostate cancer in a patient. In a specific embodiment, a method for predicting metastasis in a prostate cancer patient comprises the steps of (a) genotyping the ASPN D repeat domain length in both alleles of the patient using a polymerase chain reaction; (b) predicting metastasis in the patient if the ASPND repeat domain length is 13 in one allele and 14 in the other allele or have at least one allele with 14 D repeats as compared to other common allelic genotypes; and (c) predicting no metastasis in the patient if the ASPN D repeat domain length is 13 in both alleles as compared to other allelic genotypes.

Abstract translation: 本发明涉及癌症领域。 更具体地，本发明提供了可用于评估患者中前列腺癌的方法和组合物。 在具体实施方案中，用于预测前列腺癌患者转移的方法包括以下步骤：（a）使用聚合酶链式反应对患者的两个等位基因中的ASPN D重复域长度进行基因分型; （b）如果ASPND重复域长度在一个等位基因中为13，在其他等位基因中为14，或与其他常见等位基因型相比具有至少一个具有14个D重复的等位基因，则预测患者的转移; 和（c）与其他等位基因型相比，如果两个等位基因的ASPN D重复域长度为13，则预测患者无转移。

公开(公告)号：US20150299807A1

公开(公告)日：2015-10-22

申请号：US14646427

申请日：2013-11-21

Applicant: THE JOHNS HOPKINS UNIVERSITY

Inventor： Ashley E. ROSS ,  Edward M. SCHAEFFER

IPC: C12Q1/68 ,  A61B5/15 ,  A61B10/00 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  A61B5/15 ,  A61B10/0038 ,  A61B10/0058 ,  A61B10/007 ,  C12Q2600/112 ,  C12Q2600/158 ,  G01N33/57434 ,  G01N2800/56 ,  H01J49/0036

Abstract: The present invention relates to the field of biomarkers. More specifically, the present invention provides methods and compositions useful for diagnosing and/or prognosing prostate cancer. In a specific embodiment, a method for diagnosing prostate cancer or a likelihood thereof in a patient comprising the steps of (a) obtaining a biological sample from the patient; (b) subjecting the sample to an assay for detecting expression of one or more of ACSM2A, BDH2, C19orf51, C8orf76, CGB5, CSMD3, DAZ2, DUX4, FAM22G, FAM90A1, GABBR2, GRM3, HMMR, HOXC4, KAAG1, KRIT1, KRTAP20-1, LOC392196, LOC441956, LOC650293, LTB4R, METTL7B, NEK2, OR11H12, OR2J3, OR2L8, OR2M1P, OR2T3, OR4F5, OR52A4, OR5211, PGA3, PHACTR3, PMP2, PRAMEF6, PSG1, SIGLEC10, SOX11, SPDYE1, SSX1, TCEB3B, TCFL5, TFAP2D, TSPY2, UGT2B10, UGT2B11, UGT2B28, WDR49, and WFDC5; and (c) determining that the patient has prostate cancer or a likelihood thereof if the expression of the one or more biomarkers is increased relative to a reference non-prostate cancer sample.

Abstract translation: 本发明涉及生物标志物领域。 更具体地，本发明提供了可用于诊断和/或预测前列腺癌的方法和组合物。 在具体实施方案中，用于诊断患者中的前列腺癌或其可能性的方法，包括以下步骤：（a）从患者获得生物样品; （b）对样品进行检测，以检测ACSM2A，BDH2，C19orf51，C8orf76，CGB5，CSMD3，DAZ2，DUX4，FAM22G，FAM90A1，GABBR2，GRM3，HMMR，HOXC4，KAAG1，KRIT1，KRTAP20中的一种或多种的表达 -1，LOC392196，LOC441956，LOC650293，LTB4R，METTL7B，NEK2，OR11H12，OR2J3，OR2L8，OR2M1P，OR2T3，OR4F5，OR52A4，OR5211，PGA3，PHACTR3，PMP2，PRAMEF6，PSG1，SIGLEC10，SOX11，SPDYE1，SSX1，TCEB3B ，TCFL5，TFAP2D，TSPY2，UGT2B10，UGT2B11，UGT2B28，WDR49和WFDC5; 如果一个或多个生物标志物的表达相对于参照非前列腺癌样品增加，则确定患者具有前列腺癌或其可能性。